Prevalence of CCR5-tropic HIV-1 Among Treatment-Experienced Individuals in Spain

REFERENCES

• Kwa D, Vingerhoed J, Boeser B, Schuitemaker H. Increased in vitro cytopathicity of CC chemokine receptor 5-restricted human immunodeficiency virus type 1 primary isolates correlates with a progressive clinical course of infection. J Infect Dis. 2003;187(9):1397–1403.
   PubMed Web of Science ®Google Scholar
• Singh A, Collman RG. Heterogeneous spectrum of core-ceptor usage among variants within a dualtropic human immunodeficiency virus type 1 primary-isolate quasispe-cies. J Virol. 2000;74(21)10229–10235.
   Web of Science ®Google Scholar
• Richman DD, Bozzette SA. The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression. J Infect Dis. 1994;169(5):968–974.
   PubMed Web of Science ®Google Scholar
• Tersmette M, de Goede RE, Al BJ, et al. Differential syncytium-inducing capacity of human immunodeficiency virus isolates: frequent detection of syncytium-inducing isolates in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. J Virol. 1988;62(6):2026–2032.
   PubMed Web of Science ®Google Scholar
• Brumme ZL, Goodrich J, Mayer HB, et al. Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals. J Infect Dis. 2005;192 (3):466–474.
   PubMed Web of Science ®Google Scholar
• Dau B, Holodniy M. Novel targets for antiretroviral therapy: clinical progress to date. Drugs. 2009;69(1):31–50.
   PubMed Web of Science ®Google Scholar
• Gulick RM, Lalezari J, Goodrich J, et al. Maraviroc for pre-viously treated patients with R5 HIV-1 infection. N Engl J Med. 2008;359(14)1 429–1441.
   Web of Science ®Google Scholar
• Coakley E, Petropoulos CJ, Whitcomb JM. Assessing chemokine co-receptor usage in HIV. Curr Opin Infect Dis. 2005;18(1):9–15.
   PubMed Web of Science ®Google Scholar
• Whitcomb JM, Huang W, Fransen S, et al. Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism. Antimicrob Agents Chemother 2007;51(2):566–575.
   PubMed Web of Science ®Google Scholar
• Moyle GJ, Wildfire A, Mandalia S, et al. Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection. J Infect Dis. 2005;191(6):866–872.
   PubMed Web of Science ®Google Scholar
• Melby T, Despirito M, Demasi R, Heilek-Snyder G, Greenberg ML, Graham N. HIV-1 coreceptor use in triple-class treatment-experienced patients: baseline preva-lence, correlates, and relationship to enfuvirtide response. J Infect Dis. 2006; 194(2):238–246.
   PubMed Web of Science ®Google Scholar
• Wilkin TJ, Su Z, Kuritzkes DR, et al. H IV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211. Clin Infect Dis. 2007;44(4):591–595.
   PubMed Web of Science ®Google Scholar
• Hunt PW, Harrigan PR, Huang W, et al. Prevalence of CXCR4 tropism among antiretroviral-treated HIV-1-infected patients with detectable viremia. J Infect Dis. 2006;194(7):926–930.
   PubMed Web of Science ®Google Scholar
• Delobel P, Sandres-Saune K, Cazabat M, et al. R5 to X4 switch of the predominant HIV-1 population in cellular res-ervoirs during effective highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2005;38(4):382–392.
   PubMed Web of Science ®Google Scholar
• Boucher CAB, O'Sullivan E, Mulder JW, Ramautarsing C, Kellam P, Darby G, et al. Ordered appearance of zidovu-dine resistant mutations during treatment of 18 human immunodeficiency virus positive subjects. J Infect Dis. 1992;165:105–110.
   PubMed Web of Science ®Google Scholar
• Karlsson I, Antonsson L, Shi Y, et al. HIV biological vari-ability unveiled: frequent isolations and chimeric receptors reveal unprecedented variation of coreceptor use. AIDS. 2003;17(18):2561–2569.
   PubMed Web of Science ®Google Scholar
• Skrabal K, Trouplin V, Labrosse B, et al. Impact of anti-retroviral treatment on the tropism of HIV-1 plasma virus populations. AIDS. 2003;17(6):809–814.
   PubMed Web of Science ®Google Scholar
• Briz V, Poveda E, del Mar Gonzalez M, Martin-Carbonero L, Gonzalez-Gonzalez R, Soriano V. Impact of antiretroviral therapy on viral tropism in HIV-infected patients followed longitudinally for over 5 years. J Antimicrob Chemother. 2008;61(2):405–410.
   PubMed Web of Science ®Google Scholar
• Skrabal K, Low AJ, Dong W, et al. Determining human immunodeficiency virus coreceptor use in a clinical setting: degree of correlation between two phenotypic assays and a bioinformatic model. J Clin Microbiol. 2007;45(2):279–284.
   PubMed Web of Science ®Google Scholar
• Poveda E, Briz V, Quinones-Mateu M, Soriano V. HIV tropism: diagnostic tools and implications for disease progression and treatment with entry inhibitors. AIDS. 2006;20(10):1359–1367.
   PubMed Web of Science ®Google Scholar
• Soulie C, Malet I, Lambert-Niclot S, et al. Primary geno-typic resistance of HIV-1 to CCR5 antagonists in CCR5 antagonist treatment-naive patients. AIDS. 2008;22(16): 2212–2214.
   PubMed Web of Science ®Google Scholar
• Dorr P, Westby M, Dobbs S, et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spec-trum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 2005;49(11):4721–4732
   PubMed Web of Science ®Google Scholar
• Genebat M, Ruiz-Mateos E, Leon JA, Gonzalez-Serna A, Pulido I, Rivas I. Correlation between the Trofile test and virological response to a short-term maraviroc expo-sure in HIV-infected patients. J Antimicrob Chemother. 2009;64(4):845–849. Epub 2009 Aug 11..
   PubMed Web of Science ®Google Scholar
• Robertson D. US FDA approves new class of HIV thera-peutics. Nat Biotechnol. 2003;21(5):470–471.
   PubMed Web of Science ®Google Scholar
• EMEA. European Public Assessment Report (EPAR): Celsentri. In: http://www.emea.europa.eu/humandocs/PDF5/EPAR/celsentri/H-811-en1.pdf.
   Google Scholar
• Hirsch MS, Gunthard HF, Schapiro JM, et al. Antiretrovi-ral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis. 2008;47(2):266–285.
   PubMed Web of Science ®Google Scholar
• Harrigan PR, Swenson LC, Dong W, et al. Quantification of HIV tropism by "deep" sequencing shows a broad dis-tribution of prevalence of X4 variants in clinical samples associated with virological outcomes. In: 16th Conference on Retroviruses and Opportunistic Infections. February 8–11, 2009; Montreal, Canada. Abstract 680..
   Google Scholar
• Nazari R, Joshi S. CCR5 as target for HIV-1 gene therapy. Curr Gene Ther 2008;8(4):264–272.
   PubMed Web of Science ®Google Scholar